PubMed دسترسی آزاد

Epithelial QKI Protects Against Emphysema by Maintaining Mitochondrial Integrity.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

Single-cell transcriptomic profiling of chronic obstructive pulmonary disease (COPD) lungs identified QKI, an RNA-binding protein, as a candidate emphysema-associated gene, but its epithelial role in COPD pathobiology remains unclear. We show that QKI expression is reduced in human COPD lungs and that alveolar type 2 epithelial (AT2) cell QKI protein levels correlate strongly with spirometric indices and diffusing capacity (DL CO ). Lung epithelium-specific QKI knockout mice (QKI Δ/Δ ) developed spontaneous airspace enlargement with emphysema-like mechanics, and QKI-deficient AT2 cells showed impaired spheroid colony formation and increased apoptosis. Integrated transcriptomic and proteomic analyses of primary AT2 cells revealed a selective reduction in functional mitochondrial (respiratory-chain and metabolic) protein abundance despite relatively preserved transcript levels, consistent with mitochondrial transcriptome-proteome discordance. QKI loss increased mtDNA abundance and TOMM20 staining but decreased ATP5A, indicating accumulation of structurally increased but functionally dysfunctional mitochondria. In human epithelial cells, CRISPR-mediated QKI deficiency reduced oxidative respiration, increased glycolytic reliance, elevated mitochondrial ROS and membrane potential, and increased apoptosis; these phenotypes were partially rescued by QKI re-expression. These findings identify epithelial QKI as a regulator of mitochondrial integrity and stress tolerance in COPD.

متن کامل اصلی

نسخه دارای مجوز در منبع علمی در دسترس است.

لینک مستقیم از metadata منبع گرفته شده و در تب جدید باز می‌شود.

باز کردن متن کامل
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

Transcriptional landscape of coding-noncoding RNA interactions in gallstone-associated and de-novo gallbladder carcinoma.

Gallbladder carcinoma (GBC) is an aggressive malignancy characterized by late-stage presentation, poor prognosis, and limited therapeutic options. Gallstones (GS) represent a major risk factor and are implicated in the majority of GBC cases; however, the molecular distinctions between GS-associated GBC (GBCGS) and GS-independent/de novo GBC (dnGBC) remain poorly defined. To date, no GBC subtype-specific molecular biomarkers have been e…

PubMed2026

Integration of network toxicology, machine learning and single-cell sequencing identifies candidate molecular links between air pollutants and hepatocellular carcinoma.

BACKGROUND: Epidemiological studies link long-term air pollution to an increased risk of hepatocellular carcinoma (HCC), but the underlying toxicological targets remain poorly understood. We used an integrative computational framework to identify and prioritize candidate molecular mediators potentially linking pollutant-associated gene signatures with hepatocarcinogenesis. METHODS: We retrieved pollutant-responsive genes associated wit…

PubMed2026

Single-cell transcriptome analysis in ovarian steroid cell tumors-not otherwise specified.

BACKGROUND: Ovarian steroid cell tumors-not otherwise specified (SCT-NOS) is a rare category of sex cord-stromal tumor, however, its pathophysiology is unclear. A comprehensive cellular atlas of ovarian SCT-NOS remains lacking. METHODS: We reported a case of a 41-year-old woman with hyperandrogenism for whom histopathological analysis confirmed the presence of ovarian SCT-NOS. This study utilized single-cell RNA sequencing in a case of…

PubMed2026

FcRn inhibitors in the treatment of CIDP.

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated syndrome that causes progressive and relapsing weakness and sensory loss. Evidence-based treatments that have been shown to lessen disability, improve impairment, and prevent relapse include immunoglobulins, corticosteroids, and plasma exchange. While these therapeutics are beneficial to most patients, not all patients respond, residual deficits are …